Skip to main content
Advicenne logo

Advicenne — Investor Relations & Filings

Ticker · ALDVI ISIN · FR0013296746 LEI · 969500YT5VMEYAYODW34 PA Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2024-11-28 Report Publication Anno…
Country FR France
Listing PA ALDVI

About Advicenne

https://advicenne.com

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing treatments for rare renal diseases. The company focuses on addressing unmet medical needs in nephrology for both children and adults. Its lead product, Sibnayal®, is an approved treatment for distal Renal Tubular Acidosis (dRTA). Advicenne is committed to improving the lives of patients with rare kidney conditions by developing therapeutics, including pediatric-friendly formulations, suitable for patients of all ages.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a press release from Advicenne announcing its '2025 financial communication calendar'. It lists dates for future events like '2024 sales release', '2024 annual financial statement', and 'AGM'. Since the document itself is an announcement about the *timing* and *publication schedule* of other reports and events, rather than being one of the reports itself (like an ER, 10-K, or AGM material), it fits the definition of a Report Publication Announcement (RPA). The document length (3024 chars) is short, supporting the RPA classification over a full report classification.
2024-11-28 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing significant regulatory milestones achieved by Advicenne with the US FDA regarding its drug ADV7103, specifically positive opinions allowing for US marketing authorization application submission without further clinical studies for one indication (dRTA) and constructive discussions for another (cystinuria). It also mentions accelerating partnership outlook and upcoming analyst meetings. This type of announcement, detailing key operational and regulatory achievements, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on key financial/operational updates rather than being a full financial report (like 10-K or IR) or a transcript (CT), and it is a formal announcement distributed via Business Wire, it best fits the Earnings Release (ER) category, which covers initial announcements of periodical results/key highlights, even if the primary focus here is regulatory progress rather than quarterly revenue figures. Given the context of pharmaceutical development updates, ER is often used for major pipeline news that impacts future earnings potential. It is not a proxy statement (DEF 14A), a formal annual report (10-K), or a simple notice of dividend (DIV). It is a substantial announcement, making ER more appropriate than the general fallback RNS.
2024-10-01 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated October 1, 2024, announcing significant positive developments regarding the drug ADV7103, specifically favorable opinions from the US FDA concerning regulatory submissions for two indications (ATRd and cystinuria). It details clinical data acceptance, future filing timelines (AMM filing planned for 2025), and progress in partnership discussions. This content structure—a formal announcement of key operational and regulatory milestones, often released outside of standard quarterly reporting cycles—is characteristic of an Earnings Release (ER) or a general press release announcing material news. Since it focuses on key operational achievements and regulatory progress rather than a full set of financial statements (like 10-K or IR) or a transcript (CT), 'Earnings Release' (ER) is the most appropriate classification for a material announcement of this nature, even if it's not strictly tied to a quarterly earnings report date. It is not a formal regulatory filing form (like 10-K or DEF 14A), nor is it a simple announcement of a report publication (RPA).
2024-10-01 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document explicitly states it reports the 'First Half financial results as of June 30, 2024'. It contains detailed semi-annual financial data, including a comparative table for H1 2024 vs H1 2023, management commentary on performance, and operating highlights for the six-month period. This structure perfectly matches the definition of a comprehensive financial report for a period shorter than a year, which corresponds to the Interim / Quarterly Report (IR) category. It is not a brief announcement (RPA/ER) but the detailed report itself, and its length (12,892 chars) confirms it is substantial. H1 2024
2024-09-18 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "Advicenne présente ses résultats financiers semestriels au 30 juin 2024" (Advicenne presents its half-year financial results as of June 30, 2024). It contains a detailed table of financial results (revenus, charges, résultat net) for the six-month period ending June 30, 2024, compared to the previous year. It explicitly mentions that the 'rapport financier semestriel est accessible sur le site internet de la société' (the half-year financial report is accessible on the company's website), but the content provided is the substance of those results, including management commentary and key figures. This structure—a press release summarizing and presenting the core figures of a periodic financial report for a period shorter than a year (six months)—is characteristic of an Interim/Quarterly Report (IR). It is not the full Annual Report (10-K), nor is it just a brief announcement of publication (RPA). H1 2024
2024-09-18 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is a press release dated July 18, 2024, announcing that Advicenne's gross sales reached 2.4 million euros for the first half of 2024 (S1 2024), showing an 8.8% increase compared to the previous year. It details sales figures for specific products (Sibnayal®, Likozam®, Levidcen®) and provides updates on regulatory progress (ADV7103) and cash runway. This content structure—a summary of financial performance for a specific interim period (S1 2024) released via a press announcement—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (which would be an IR) nor the annual report (10-K). It is a concise announcement of key results. H1 2024
2024-07-18 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.